Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study.

In the population with PD-L1 CPS of 1–4, although the PFS only showed a trend toward improvement in the combination group (HR, 0.54; 95% CI, 0.22–1.30; mPFS,10.2 vs 4.6 months) compared to chemotherapy alone, the OS did show a significant prolongation (16.0 vs 8.8 months; HR, 0.24; 95% CI, 0.08–0.70) (Figs. 2 E and F).

also in 53,322 other papers